Discontinued — last reported Q4 '24
Noxafil — Sales
Merck & Co. Noxafil — Sales decreased by 13.4% to $71.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric declined by 23.7%, from $93.00M to $71.00M. Over 3 years (FY 2021 to FY 2024), Noxafil — Sales shows a downward trend with a -11.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests successful market penetration or expanded clinical adoption, while a decrease may indicate increased generic competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total annual revenue generated from the sale of the specific antifungal medication product li...
Peer comparison
Comparable to specific product revenue lines in other pharmaceutical companies, often evaluated against the lifecycle stage of the drug and the presence of generic or biosimilar alternatives.
mrk_segment_noxafil_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $132.00M | $128.00M | $124.00M | $115.00M | $121.00M | $124.00M | $116.00M | $120.00M | $111.00M | $102.00M | $93.00M | $112.00M | $89.00M | $82.00M | $71.00M |
| QoQ Change | — | -3.0% | -3.1% | -7.3% | +5.2% | +2.5% | -6.5% | +3.4% | -7.5% | -8.1% | -8.8% | +20.4% | -20.5% | -7.9% | -13.4% |
| YoY Change | — | — | — | — | -8.3% | -3.1% | -6.5% | +4.3% | -8.3% | -17.7% | -19.8% | -6.7% | -19.8% | -19.6% | -23.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s noxafil — sales?
- Merck & Co. (MRK) reported noxafil — sales of $71.00M in Q4 2024.
- How has Merck & Co.'s noxafil — sales changed year-over-year?
- Merck & Co.'s noxafil — sales decreased by 23.7% year-over-year, from $93.00M to $71.00M.
- What is the long-term trend for Merck & Co.'s noxafil — sales?
- Over 3 years (2021 to 2024), Merck & Co.'s noxafil — sales has grown at a -11.9% compound annual growth rate (CAGR), from $518.00M to $354.00M.
- What does noxafil — sales mean?
- The total annual revenue generated by the sales of the Noxafil antifungal product line.